RM
Therapeutic Areas
Biodesix Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Nodify XL2® | Lung Nodule Risk Assessment (Malignant vs. Benign) | Commercial |
| Nodify CDT® | Lung Nodule Risk Assessment (Malignant vs. Benign) | Commercial |
| GeneStrat® | Therapy Selection & Monitoring in Non-Small Cell Lung Cancer (NSCLC) | Commercial |
| VeriStrat® | Prognostic & Predictive Test for NSCLC Therapy | Commercial |
| IQLung™ | Integrated Diagnostic Report for NSCLC | Commercial |
| COVID-19 Severity Test | Predicting Disease Severity in Hospitalized COVID-19 Patients | Development |
Leadership Team at Biodesix
SH
Scott Hutton
Chief Executive Officer
RH
Robin Harper Cowie
Chief Financial Officer
GA
Gary A. Pestano
Chief Development Officer & Vice President of Laboratory Operations
DB
David Brunel
Chief Executive Officer (Previous)
RP
Ryan Parasch
Senior Vice President of Commercial
PO
Paul O’Donnell
Senior Vice President of Strategy & Corporate Development
KS
Katherine S. Zanotti
Chairperson of the Board of Directors
HM
Hugh M. Jones III
Director
SL
Stephen L. Hoffman
Director
AJ
Andrea J. Walsh
Director